Introduction
============

Lung cancer is one of the most common types of cancer and is the leading cause of cancer-related mortality wordwide. Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the most common types of lung cancer, of which NSCLC accounts for approximately 85% of all cases ([@b1-or-39-03-0929]). Lung adenocarcinoma is the most common subtype of NSCLC (40%) in many countries ([@b2-or-39-03-0929],[@b3-or-39-03-0929]). To date, many genetic factors have been proposed to be involved in lung adenocarcinoma, including several tumour-suppressor genes (TP53, CDKN2A, STK11, NF1, ATM, RB1, and APC) ([@b4-or-39-03-0929],[@b5-or-39-03-0929]). Several new targeted therapies have resulted in considerable clinical benefits for cancer patients in recent years, as well as a deeper understanding of lung adenocarcinoma at the molecular level. One example of a new targeted therapy is epidermal growth factor receptor (EGFR) and KRAS targeted gene therapy ([@b6-or-39-03-0929],[@b7-or-39-03-0929]). However, targeted gene therapy is mainly used when patients have special characteristics. EGFR mutations occur more frequently in female lung adenocarcinoma patients with a non-smoking history ([@b8-or-39-03-0929]). HER2 mutations tend to occur in non-smoking males ([@b9-or-39-03-0929]). In contrast, KRAS mutations occur during the early development of smoking-related lung adenocarcinoma ([@b10-or-39-03-0929]). Based on these observations, there is a need to develop individualized treatment programs for patients with unique clinical characteristics. Lung adenocarcinoma is caused by a combination of genetic and environmental effects ([@b11-or-39-03-0929]).

More recently, the incidence of lung adenocarcinoma has increased in smokers ([@b12-or-39-03-0929]). Tobacco smoke contains a mixture of harmful compounds and carcinogens ([@b13-or-39-03-0929]). Therefore, smoking plays an important role in the development of lung adenocarcinoma. Although the correlation between smoking and lung adenocarcinoma has been demonstrated in previous studies, a meta-analysis of the gene mutations in a large number of tissue samples that considers the smoking history in lung adenocarcinoma has not yet been conducted ([@b14-or-39-03-0929]). This large scale analysis can reduce the differences caused by different research conditions and can integrate the results from previous studies to evaluate the issue from another point of view. The development of microarray methods for large scale analysis of gene expression makes it possible to perform a more comprehensive analysis for potential genes and molecular pathways associated with lung adenocarcinoma in smoking patients ([@b15-or-39-03-0929]). DNA microarray analysis has been applied to investigate whole genomic expression profiles and physiological mechanisms in health and disease ([@b16-or-39-03-0929],[@b17-or-39-03-0929]). Therefore, a high-throughput microarray experiment was designed to analyse the genetic expression patterns and identify potential genes to target for lung adenocarcinoma ([@b18-or-39-03-0929]). Meta-analysis provides a powerful tool for analysing microarray experiments by combining data from multiple studies ([@b19-or-39-03-0929]). Genes identified by meta-analysis tend to overlap with genes identified in other studies, suggesting increased reliability ([@b20-or-39-03-0929]). In addition to providing a new perspective, this research topic will further the understanding of the relationship between smoking and lung adenocarcinoma.

The aim of this study was to identify possible candidate genes for personalized treatment for lung adenocarcinoma patients with a history of smoking to provide patients with better treatment options and ensure a good prognosis. Therefore, we conducted a meta-analysis using the same platform of gene expression profile data that associated smoking with lung adenocarcinoma tissue.

Materials and methods
=====================

### Selection of microarray datasets for meta-analysis

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines published in 2009, we performed a detailed and comprehensive search of microarray datasets in the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/geo/>).

### Meta-analysis data

To maintain objectivity, the data were simultaneously extracted by two independent reviewers from the original search. Any discrepancies that arose between the two reviewers were resolved by consultation with a third reviewer. The terms 'lung neoplasms' and 'lung cancer' were considered keywords during our search for this study. In addition, studies that reported non-human data were excluded in the selection process for microarray datasets. Finally, 583 datasets were obtained from searching the Gene Expression Omnibus (GEO) database. Datasets with \>20,288 samples were elected for the study. We included a dataset in the meta-analysis if it contained i) all samples on the Affymetrix Human Genome U133 Plus 2.0 Array platform, ii) samples from lung adenocarcinoma tissue and iii) samples with valid smoking statuses. According to the criteria, the four datasets that were selected from the 288 datasets included 477 lung adenocarcinoma tissues with valid smoking statuses. Then, we downloaded the lung adenocarcinoma tissue files (CEL) of the four microarray datasets from the GEO database with accession numbers GSE12667, GSE31210, GSE40791, and GSE50081. The four datasets included 477 lung adenocarcinoma patients; 327 of which were smokers, and 150 were non-smokers; the smokers included former smokers, current smokers and ex-smokers.

### Meta-analysis of microarray datasets using the same platform

We conducted the meta-analysis of gene expression profiles of the selected four microarray datasets by using R statistical software (<http://www.r-project.org/>) with the same platform. Prior to the meta-analysis, we performed data normalization of the four datasets using R statistical software. Then, we processed the meta-analysis using the MAMA, mataMA, affyPLM and CLL packages in R statistical software according to the t-test and z-score methods. During the meta-analysis with R statistical software, a list of differentially expressed genes (DEGs) (upregulated or downregulated) were identified based on the P-values (where the threshold was \<0.005) and z-scores (where the threshold was an absolute value \>3).

### Enrichment analysis of the GO function and KEGG pathway

It is important to understand the biological implications of the identified DEGs in lung adenocarcinoma tissue. According to the meta-analysis results, the most significant 200 DEGs (100 upregulated and 100 downregulated) were selected for enrichment analysis. Then, we conducted the functional enrichment analysis of the gene ontology (GO) function and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway using the WEB-based GEne SeT AnaLysis Toolkit (<http://bioinfo.vanderbilt.edu/webgestalt/login.php>) under a significance threshold of P\<0.05.

### PPI network analysis

To further understand and predict the biological activity of the identified DEGs that were based on the results of the GO function and KEGG pathway enrichment analyses, we conducted a protein-protein interaction (PPI) network using the Cytoscape software. Prior to this analysis, we imported the DEG-encoding proteins into a protein-protein interaction (PPI) network, which was downloaded from the Biological General Repository for Interaction Datasets (BioGRID, <http://thebiogrid.org/>).

Results
=======

### Selection of microarray datasets related to lung adenocarcinoma for meta-analysis

From the microarray datasets retrieved from the GEO database of NCBI, we extracted 477 GEO lung adenocarcinoma samples that belonged to four microarray datasets, which met our criteria for meta-analysis (see Materials and methods, and [Fig. 1](#f1-or-39-03-0929){ref-type="fig"}). All four GEO series (GSEs) were microarray datasets that used only lung adenocarcinoma tissue with valid smoking statuses. The GEO Platform Files (GPLs) from the four datasets (GSE12667, GSE31210, GSE40791 and GSE50081) were obtained using the Affymetrix 'Gene Chip' ([Table I](#tI-or-39-03-0929){ref-type="table"}).

### Identification of upregulated or downregulated DEGs through meta-analysis

We performed the meta-analysis of gene expression profiles according to t-test and z-score methods using MAMA, mataMA, affyPLM and CLL packages in R statistical software on the same platform. According to the P-value (where the threshold was \<0.005) and z-score (where the threshold was an absolute value \>3), we were able to identify a total of 2,932 DEGs, including 1,806 upregulated and 1,126 downregulated genes using Venny 2.0 (<http://bioinfogp.cnb.csic.es/tools/venny/index.html>). The 200 genes that showed maximum upregulation and downregulation are shown in [Tables II](#tII-or-39-03-0929){ref-type="table"} and [III](#tIII-or-39-03-0929){ref-type="table"}, and the overlapping DEGs based on P-values and z-scores are shown in [Fig. 2](#f2-or-39-03-0929){ref-type="fig"}. A subset of the top 50 DEGs (25 upregulated and 25 downregulated) in the four microarray datasets were visualized with heat maps using the Mev software and are shown in [Figs. 3](#f3-or-39-03-0929){ref-type="fig"}--[6](#f6-or-39-03-0929){ref-type="fig"}.

### Enrichment analysis of the GO function and KEGG pathway for the top 100 upregulated and downregulated DEGs

We classified the 200 DEGs that were identified through meta-analysis according to the GO hierarchy into functional categories (biological process, molecular function, and cellular component) and based on the KEGG pathway, with a significance threshold of \<0.05. The most significant GO terms under the biological processes category were enriched in the following descending order: 'cell cycle phase' (GO:0022403), 'M phase of mitotic cell cycle' (GO:0000087) and 'mitotic cell cycle' (GO:0000278). The most enriched GO terms under the molecular functions and cellular components categories were 'protein binding' (GO:0005515) and 'nuclear part' (GO:0044428). The most enriched KEGG pathway terms were (in descending order): 'Cell cycle' (kegg:04110), 'Oocyte meiosis' (kegg:04114) and 'Ubiquitin mediated proteolysis' (kegg:04120) ([Tables IV](#tIV-or-39-03-0929){ref-type="table"} and [V](#tV-or-39-03-0929){ref-type="table"}).

### PPI network analysis of the DEGs

To understand the biological meaning of the 8 upregulated DEGs identified by the KEGG pathway under the cell cycle pathway at the protein level, we constructed a PPI network for the proteins encoded by the 8 DEGs with interactions that included 541 nodes and 671 edges as shown in [Fig. 7](#f7-or-39-03-0929){ref-type="fig"}.

Discussion
==========

In the present study, we showed that genes are differentially expressed in lung adenocarcinoma in smoking and non-smoking patients. Some genes that showed the highest expression levels were found in lung adenocarcinoma patients who had a smoking history. Smoking consistently plays an important role in the development of lung adenocarcinoma. Cigarette smoke contains over 400 identified chemicals, at least 250 of which are implicated in tumour initiation and promotion ([@b21-or-39-03-0929]). It is estimated that more than 50 chemicals in tobacco smoke cause cancers ([@b22-or-39-03-0929]). Cigarette smoke is by far the most widespread link between exposure to known carcinogens and death from lung cancer ([@b23-or-39-03-0929]). Lung adenocarcinoma is one of the main types of lung cancer in smokers and cannot be successfully treated with traditional treatments. Therefore, the effects of cigarette smoke on the genes that are implicated in lung adenocarcinoma are critical to increase our understanding of the carcinogenesis and in finding targeted genes. In our study, we found that the cell cycle pathway was significantly altered in lung adenocarcinoma tissues from patients with a smoking history.

Using several perspectives would allow us to characterise the underlying mechanisms of lung adenocarcinoma in smokers. Thus, we performed a meta-analysis of four independent microarray datasets using the same platform. The large number of DEGs identified in our study implies that our approach produces more reliable results in identifying differences in gene expression levels among lung adenocarcinoma patients who either had a smoking or a non-smoking history. In this study, the microarray expression datasets derived from lung adenocarcinoma tissue with patients with either a smoking or non-smoking history were publicly available. A number of previous studies have molecularly characterised the genetic profiles in lung cancer patients with or without a smoking history. The present investigation focused on a relatively larger cohort with 477 lung adenocarcinoma tissues from 327 smoking patients and 150 non-smoking patients, thereby providing a more powerful analysis. Our study results were highly consistent with previous DEG analyses, supporting the utility and validity of this analytical approach. Additionally, it also revealed that multiple biological processes and pathways, including cell cycle phase and the cell cycle pathway, were significantly affected in lung adenocarcinoma tissues from smoking patients compared to the non-smoking patients. Consistently, many previous studies have revealed that cigarette smoke extract accelerated premature gene mutations in the cell cycle pathway. Cigarette smoke extract alters the cell cycle via the phospholipid transfer protein/transforming growth factor-β1/cyclinD1/CDK4 pathway ([@b24-or-39-03-0929]). Cigarette smoking is a major factor for many cancers including, pancreatic cancer, human ovarian cancer and colon cancer ([@b25-or-39-03-0929]--[@b27-or-39-03-0929]). This study identified the 8 overexpressed genes in the cell cycle pathway as CDC45, PLK1, CDC20, ANAPC7, CDC6, CHEK1, CCNE1 and ESPL1. According to the P-values in the meta-analysis, we identified a few significant DEGs including CDC45, CDC20, ANAPC7, CDC6, and ESPL1. Based on our meta-analysis results, these five genes may be potential target genes for the treatment of this disease.

CDC45 is a member of the highly conserved multiprotein complex including Cdc6/Cdc18. The replication factor CDC45 has essential functions in the initiation and plays an important role in the intra-S-phase checkpoint ([@b28-or-39-03-0929]). CDC45 has been found to be upregulated in many neoplasms, such as breast neoplasms, colorectal neoplasms, lung neoplasms and haematological neoplasms ([@b29-or-39-03-0929]).

CDC20 appears to act as a regulatory protein by interacting with several other proteins at multiple points in the cell cycle ([@b30-or-39-03-0929]). The CDC20 gene might play an important role in the malignancy of NSCLC. Additionally, CDC20 has been found to be upregulated in lung cancer patients with a smoking history ([@b31-or-39-03-0929]). In addition, through this analysis, we identified the overexpression of the CDC20 gene in lung adenocarcinoma patients who had a smoking history compared to the non-smoking patients. Combined with previous research, our analysis demonstrates that the CDC20 gene might play an important role in the treatment of lung adenocarcinoma in smoking patients.

ANAPC7 is an E3 ligase enzyme that ubiquinates various proteins involved in the cell cycle ([@b32-or-39-03-0929]). This protein complex may have a pivotal role in the cell cycle control affecting pathological conditions such as cancer ([@b33-or-39-03-0929]). ANAPC mutations have been reported in lung squamous cell carcinoma and small cell lung carcinoma.

CDC6, a cell cycle regulatory gene, is an essential regulator of DNA replication and plays important roles in the activation and maintenance of the checkpoint mechanism in the cell cycle ([@b34-or-39-03-0929]). CDC6 has been associated with the oncogenic activities in human cancers, such as ovarian cancer, lung cancer and prostate cancer ([@b35-or-39-03-0929],[@b36-or-39-03-0929]). However, the biological function and clinical significance of CDC6 in lung adenocarcinoma remain unclear. A previous study suggests that CDC6 is associated with the decline in lung function of ex-smoking in COPD ([@b37-or-39-03-0929]). Our study also revealed CDC6 overexpression in lung adenocarcinoma patients with a smoking history compared to non-smoking patients.

ESPL1 is a protein-coding gene, and its overexpression has been found in a variety of human cancers such as rectum adenocarcinoma, prostate carcinoma, breast carcinoma and lung carcinoma ([@b38-or-39-03-0929],[@b39-or-39-03-0929]). Consistent with earlier results, our study revealed that ESPL is overexpressed in lung adenocarcinoma in patients with a smoking history compared to those who had a non-smoking history.

Overall, the present study identified that a few genes are differentially expressed in lung adenocarcinoma samples between smoker and non-smoker patients. This observation supports previous studies; however, our analysis provides new insights that enable better understanding of the molecular mechanisms of lung adenocarcinoma in smokers, which may provide potential targets for the therapeutic design of individualized treatments for lung adenocarcinoma patients who have a smoking history.
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![Heat-map representation of the expression profiles for the top 25 upregulated and downregulated differentially expressed genes (DEGs) in the GSE50081 dataset. The clustering of the selected genes on the heat-map was performed using a hierarchical clustering algorithm that uses an average linkage method and Pearson\'s correlation coefficient.](OR-39-03-0929-g05){#f6-or-39-03-0929}

![Protein-protein interaction (PPI) network of the 8 upregulated differentially expressed genes (DEGs).](OR-39-03-0929-g06){#f7-or-39-03-0929}

###### 

Characteristic of individual studies retrieved from Gene Expression Omnibus for meta-analysis.

             Sample                                 
  ---------- -------- ------- --------------------- ---------------------------------------------
  GSE12667     40         8   Lung adenocarcinoma   Affymetrix Human Genome U133 Plus 2.0 Array
  GSE31210   111      115     Lung adenocarcinoma   Affymetrix Human Genome U133 Plus 2.0 Array
  GSE40791     82         4   Lung adenocarcinoma   Affymetrix Human Genome U133 Plus 2.0 Array
  GSE50081     94       23    Lung adenocarcinoma   Affymetrix Human Genome U133 Plus 2.0 Array

###### 

The 100 upregulated genes.

  Probe ID        Gene       P-value       z-score
  --------------- ---------- ------------- --------------
  218670_at       PUS1       1.26565E-14   −3.364765896
  202856_s\_at    SLC16A3    1.31006E-14   −3.005755138
  1553984_s\_at   DTYMK      2.73115E-14   −3.77721059
  210052_s\_at    TPX2       3.28626E-14   −3.156028484
  225620_at       RAB35      6.72795E-14   −3.977400883
  201710_at       MYBL2      1.13465E-13   −3.753904206
  200896_x\_at    HDGF       1.32117E-13   −6.606272774
  233986_s\_at    PLEKHG2    1.34559E-13   −4.721664344
  209186_at       ATP2A2     1.52767E-13   −3.331133151
  202954_at       UBE2C      1.96732E-13   −3.433957425
  234992_x\_at    ECT2       2.22933E-13   −3.540186205
  218468_s\_at    GREM1      2.91323E-13   −3.421989473
  221591_s\_at    FAM64A     3.1064E-13    −3.645233189
  223308_s\_at    WDR5       3.71925E-13   −3.441383479
  204092_s\_at    AURKA      4.20552E-13   −4.669115008
  218593_at       RBM28      5.6688E-13    −3.725504934
  204962_s\_at    SLC35F6    6.05294E-13   −3.16224673
  218726_at       HJURP      9.13047E-13   −3.516355847
  206364_at       KIF14      1.22724E-12   −3.097688744
  202870_s\_at    CDC20      1.31761E-12   −3.025537109
  212680_x\_at    PPP1R14B   1.41753E-12   −3.30292041
  220651_s\_at    MCM10      1.66711E-12   −3.962832885
  222441_x\_at    SLMO2      1.88827E-12   −3.580783528
  212541_at       FLAD1      2.68452E-12   −4.335857984
  223931_s\_at    CHFR       2.91989E-12   −5.133807637
  203612_at       BYSL       2.94276E-12   −3.332540528
  219874_at       SLC12A8    3.14992E-12   −4.228880162
  229538_s\_at    IQGAP3     3.39373E-12   −4.67663851
  38158_at        ESPL1      3.52074E-12   −4.330276826
  224753_at       CDCA5      3.8165E-12    −3.102794749
  200044_at       SRSF9      5.19895E-12   −4.335016805
  234915_s\_at    DENR       6.64646E-12   −3.045464333
  206316_s\_at    KNTC1      7.17115E-12   −3.034017863
  225468_at       PATL1      7.18048E-12   −4.555045317
  200756_x\_at    CALU       7.89546E-12   −3.573314992
  202095_s\_at    BIRC5      8.23586E-12   −3.071731969
  209464_at       AURKB      8.59246E-12   −5.290213575
  204430_s\_at    SLC2A5     9.54348E-12   −3.999406252
  219918_s\_at    ASPM       9.98956E-12   −3.385882475
  218512_at       WDR12      1.10383E-11   −3.127647757
  203702_s\_at    TTLL4      1.10745E-11   −3.222581427
  242944_at       FAM83A     1.14144E-11   −6.56980268
  206205_at       MPHOSPH9   1.17426E-11   −3.286743793
  221520_s\_at    CDCA8      1.222E-11     −3.189226567
  220011_at       AUNIP      1.32323E-11   −5.645650742
  203004_s\_at    MEF2D      1.41975E-11   −6.628593875
  204005_s\_at    PAWR       1.44695E-11   −4.589047842
  200744_s\_at    GNB1       1.57292E-11   −3.309783419
  202580_x\_at    FOXM1      1.92268E-11   −3.156340828
  201761_at       MTHFD2     2.141E-11     −3.158744955
  204603_at       EXO1       2.21381E-11   −3.093222948
  225401_at       C1orf85    2.37168E-11   −4.583223012
  228703_at       P4HA3      2.44789E-11   −4.354770166
  204709_s\_at    KIF23      2.78617E-11   −3.130038648
  212322_at       SGPL1      3.15128E-11   −3.303129755
  202779_s\_at    UBE2S      3.25431E-11   −3.246262139
  210386_s\_at    MTX1       3.28946E-11   −3.499628552
  205733_at       BLM        3.44063E-11   −3.183717987
  223307_at       CDCA3      3.49276E-11   −3.223011207
  1555943_at      PGAM5      3.49287E-11   −4.908658645
  219493_at       SHCBP1     3.69571E-11   −3.171551777
  223785_at       FANCI      4.13012E-11   −3.72118368
  212021_s\_at    MKI67      4.16123E-11   −3.291213712
  200750_s\_at    RAN        4.22222E-11   −3.060882727
  229892_at       EP400NL    4.39129E-11   −4.569469931
  204126_s\_at    CDC45      4.39451E-11   −3.107729352
  226949_at       GOLGA3     4.51967E-11   −3.569550938
  205895_s\_at    NOLC1      4.80713E-11   −3.479055682
  205691_at       SYNGR3     4.92397E-11   −6.345274404
  204641_at       NEK2       4.94367E-11   −3.260850411
  223365_at       DHX37      5.08806E-11   −6.413792983
  229610_at       CKAP2L     5.22091E-11   −3.506800101
  207590_s\_at    CENPI      5.60811E-11   −3.706888048
  224742_at       ABHD12     6.35478E-11   −3.351775356
  209052_s\_at    WHSC1      6.63429E-11   −3.610265902
  206074_s\_at    HMGA1      6.86768E-11   −3.035687751
  225554_s\_at    ANAPC7     7.7532E-11    −4.210797517
  204649_at       TROAP      8.73972E-11   −3.344919358
  212871_at       MAPKAPK5   9.64493E-11   −6.062517519
  201954_at       ARPC1B     1.04984E-10   −3.29272791
  203967_at       CDC6       1.15562E-10   −3.032999971
  205024_s\_at    RAD51      1.27276E-10   −3.317013997
  201127_s\_at    ACLY       1.40898E-10   −3.598775099
  201292_at       TOP2A      1.69439E-10   −3.586121076
  1555274_a\_at   EPT1       1.82091E-10   −3.107139925
  222077_s\_at    RACGAP1    1.98689E-10   −3.463568797
  212949_at       NCAPH      2.04934E-10   −3.123094613
  214866_at       PLAUR      2.8521E-10    −6.066208054
  209836_x\_at    BOLA2B     3.03036E-10   −3.581736948
  236957_at       CDCA2      3.37438E-10   −3.267349523
  204318_s\_at    GTSE1      3.6192E-10    −3.165321627
  222622_at       PGP        3.89473E-10   −3.166188967
  218497_s\_at    RNASEH1    4.25561E-10   −3.276072648
  218984_at       PUS7       4.45897E-10   −4.331098443
  205394_at       CHEK1      4.6472E-10    −3.071160119
  210821_x\_at    CENPA      4.95303E-10   −3.345790152
  223484_at       C15orf48   6.08452E-10   −3.301630777
  213523_at       CCNE1      6.55394E-10   −4.360746545
  209642_at       BUB1       7.26076E-10   −3.325492652
  202240_at       PLK1       8.52925E-10   −3.537560833

###### 

The 100 downregulated genes.

  Probe ID        Gene            P-value       z-score
  --------------- --------------- ------------- -------------
  225956_at       CREBRF          0             3.056084
  209740_s\_at    PNPLA4          0             8.750866
  204754_at       HLF             0             3.370263
  230163_at       GFRA1           0             3.162875
  242496_at       ART4            0             3.160279
  221518_s\_at    USP47           0             4.047036
  235830_at       NT5DC1          0             3.951365
  235155_at       BDH2            0             3.138416
  208741_at       SAP18           0             3.588813
  228692_at       PREX2           0             3.033953
  211999_at       MIR4738         0             3.297597
  227562_at       LAMTOR3         0             3.340261
  229573_at       USP9X           2.22E-16      4.870675
  205756_s\_at    F8              2.22E-16      3.20333
  229319_at       BC022047        2.22E-16      3.024973
  228411_at       PARD3B          4.44E-16      3.454669
  212425_at       SCAMP1          4.44E-16      3.064577
  213876_x\_at    ZRSR2           4.44E-16      5.174619
  239252_at       COX7B           4.44E-16      3.999039
  200933_x\_at    RPS4X           4.44E-16      5.299386
  210829_s\_at    SSBP2           4.44E-16      3.082665
  206767_at       RBMS3           6.66E-16      3.71459
  226709_at       ROBO2           6.66E-16      3.615428
  203991_s\_at    KDM6A           8.88E-16      5.796073
  227274_at       SYNJ2BP-COX16   1.11E-15      3.517758
  228504_at       SCN7A           1.78E-15      3.16819
  225998_at       GAB1            2E-15         3.00431
  218346_s\_at    SESN1           2.44E-15      3.055691
  224976_at       NFIA            3.11E-15      3.007387
  205857_at       SLC18A2         4.22E-15      3.457499
  225352_at       SEC62           6.88E-15      3.26132
  200810_s\_at    CIRBP           1.49E-14      3.072028
  200983_x\_at    CD59            2.22E-14      3.24769
  212249_at       PIK3R1          2.44E-14      4.98666
  241689_at       METTL14         3.42E-14      3.311901
  228716_at       THRB            4.88E-14      3.021776
  205259_at       NR3C2           5E-14         3.392261
  223588_at       THAP2           5.44E-14      6.445672
  201427_s\_at    SEPP1           6.02E-14      3.146142
  219427_at       FAT4            7.7E-14       3.056389
  209807_s\_at    NFIX            7.97E-14      3.105386
  201498_at       USP7            8.55E-14      3.827248
  228243_at       RP11-5C23.1     8.84E-14      3.43588
  238786_at       ANK3            1.58E-13      3.075604
  233249_at       LOC100507073    1.61E-13      3.069721
  208633_s\_at    MACF1           1.79E-13      3.260397
  226816_s\_at    KIAA1143        1.94E-13      3.431996
  208792_s\_at    CLU             2.46E-13      3.627978
  210426_x\_at    RORA            2.51E-13      3.077789
  229969_at       SEC63           2.86E-13      3.019815
  225811_at       C11orf58        2.90212E-13   3.095344537
  227847_at       EPM2AIP1        3.27738E-13   3.460553723
  201019_s\_at    EIF1AX          3.35065E-13   4.257274339
  223695_s\_at    ARSD            3.475E-13     5.635180257
  228905_at       PCM1            3.53051E-13   3.340750721
  217707_x\_at    SMARCA2         3.67262E-13   4.020194349
  225093_at       UTRN            6.21503E-13   3.138806562
  227425_at       REPS2           7.33413E-13   3.055352168
  211734_s\_at    FCER1A          8.45324E-13   3.411503985
  244007_at       ZNF462          9.36362E-13   3.786986943
  212675_s\_at    CEP68           1.00742E-12   3.307657084
  238454_at       ZNF540          1.13221E-12   3.186059238
  224889_at       FOXO3           1.14175E-12   3.853408162
  1558512_at      RP11-819C21.1   1.37579E-12   3.144887286
  213802_at       PRSS12          1.47216E-12   4.357472705
  225465_at       MAGI1           1.47393E-12   4.208157151
  223126_s\_at    C1orf21         1.56142E-12   3.186640389
  230479_at       EIF3F           1.58984E-12   3.299359045
  228448_at       MAP6            1.66223E-12   3.143593284
  217779_s\_at    PNRC2           1.91847E-12   3.246325539
  1560648_s\_at   TSPYL1          1.9309E-12    3.760805629
  212936_at       FAM172A         2.19358E-12   4.299840018
  227091_at       CCDC146         2.29194E-12   3.206298087
  221564_at       PRMT2           2.38565E-12   3.547995663
  43427_at        ACACB           2.44649E-12   3.004593504
  229384_at       CTC-429P9.3     2.57394E-12   3.228782722
  222663_at       RIOK2           2.69118E-12   3.35934368
  238472_at       FBXO9           2.69273E-12   3.562133246
  222533_at       CRBN            2.82396E-12   3.004216036
  228751_at       CLK4            3.30425E-12   3.359190366
  208832_at       ATXN10          3.36042E-12   3.408974266
  238043_at       ARID1B          3.38618E-12   3.280003422
  1559412_at      LINC00478       3.50475E-12   4.041998876
  238081_at       WDFY3-AS2       3.68106E-12   3.077236586
  228760_at       SRSF8           4.13358E-12   3.538832842
  235240_at       ATXN3           4.47198E-12   3.59474854
  240806_at       RPL15           5.22404E-12   3.229351616
  228027_at       GPRASP2         5.30198E-12   3.191435286
  209815_at       PTCH1           5.63194E-12   3.080285017
  208760_at       UBE2I           6.31295E-12   3.075043093
  229317_at       KPNA5           6.53722E-12   3.749106743
  228420_at       PDCD2           7.1736E-12    3.442288871
  227520_at       TXLNG           7.54685E-12   5.386988658
  244294_at       GTF2H5          7.70273E-12   4.035395557
  204011_at       SPRY2           7.75358E-12   3.811245705
  209614_at       ADH1B           7.83396E-12   3.188622844
  226774_at       FAM120B         8.43059E-12   3.286960689
  235612_at       PRPF38A         1.023E-11     3.636955078
  232122_s\_at    VEPH1           1.20886E-11   3.052642894
  216342_x\_at    RPS4XP2         1.22578E-11   6.967247025

###### 

The enrichment based on the top 10 GO functions shows the top 100 upregulated and downregulated DEGs.

  GO ID        GO term                                              No. of Genes   P-value
  ------------ ---------------------------------------------------- -------------- ----------
  GO:0022403   Cell cycle phase                                       48           3.26E-18
  GO:0000087   M phase of mitotic cell cycle                          33           6.78E-18
  GO:0022402   Cell cycle process                                     52           6.78E-18
  GO:0000278   Mitotic cell cycle                                     45           6.78E-18
  GO:0044428   Nuclear part                                           70           6.12E-10
  GO:0031981   Nuclear lumen                                          64           1.48E-09
  GO:0044422   Organelle part                                       112            1.63E-09
  GO:0005515   Protein binding                                      112            1.27E-05
  GO:0042975   Peroxisome proliferator activated receptor binding       3          0.0097
  GO:0019899   Enzyme binding                                         25           0.0135

GO, gene ontology; DEGs, differentially expressed genes.

###### 

The enrichment based on the top KEGG pathway shows the top 100 upregulated and downregulated DEGs.

  KEGG ID      KEGG pathway                          No. of Genes   P-value
  ------------ ------------------------------------- -------------- ----------
  kegg:04110   Cell cycle                            8              2.45E-06
  kegg:04114   Oocyte meiosis                        7              9.76E-06
  kegg:04120   Ubiquitin mediated proteolysis        5              0.0032
  kegg:03013   RNA transport                         5              0.0036
  kegg:04610   Complement and coagulation cascades   3              0.013
  kegg:04115   p53 signalling pathway                3              0.013
  kegg:05200   Pathways in cancer                    6              0.013
  kegg:03060   Protein export                        2              0.0144
  kegg:03008   Ribosome biogenesis in eukaryotes     3              0.0152
  kegg:03440   Homologous recombination              2              0.0168

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.

[^1]: Contributed equally
